Show simple item record

Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses

dc.contributor.authorNguyen, Long Chi
dc.contributor.authorYang, Dongbo
dc.contributor.authorNicolaescu, Vlad
dc.contributor.authorBest, Thomas J.
dc.contributor.authorRandall, Glenn
dc.contributor.authorRosner, Marsha Rich
dc.contributor.authorNational COVID Cohort Collaborative Consortium
dc.date2022-08-11T08:08:11.000
dc.date.accessioned2022-08-23T15:45:41Z
dc.date.available2022-08-23T15:45:41Z
dc.date.issued2022-02-25
dc.date.submitted2022-04-07
dc.identifier.citation<p>Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D, Gabbard JD, Chen SN, Ohtsuki T, Friesen JB, Drayman N, Mohamed A, Dann C, Silva D, Robinson-Mailman L, Valdespino A, Stock L, Suárez E, Jones KA, Azizi SA, Demarco JK, Severson WE, Anderson CD, Millis JM, Dickinson BC, Tay S, Oakes SA, Pauli GF, Palmer KE; National COVID Cohort Collaborative Consortium, Meltzer DO, Randall G, Rosner MR. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2022 Feb 25;8(8):eabi6110. doi: 10.1126/sciadv.abi6110. Epub 2022 Feb 23. PMID: 35050692.. <a href="https://doi.org/10.1126/sciadv.abi6110">Link to article on publisher's site</a></p>
dc.identifier.issn2375-2548 (Linking)
dc.identifier.doi10.1126/sciadv.abi6110
dc.identifier.pmid35050692
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27583
dc.description<p>The UMass Center for Clinical and Translational Science (UMCCTS), UL1TR001453, helped fund this study.</p> <p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractThe spread of SARS-CoV-2 and ongoing COVID-19 pandemic underscores the need for new treatments. Here we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1alpha RNase endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against use of non-medical formulations including edibles, inhalants or topicals as a preventative or treatment therapy at the present time.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=35050692&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectcannabidiol
dc.subjectCBD
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectUMCCTS funding
dc.subjectImmunology and Infectious Disease
dc.subjectInfectious Disease
dc.subjectMicrobiology
dc.subjectVirus Diseases
dc.titleCannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
dc.typeJournal Article
dc.source.journaltitleScience advances
dc.source.volume8
dc.source.issue8
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1390&amp;context=covid19&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/382
dc.identifier.contextkey28518647
refterms.dateFOA2022-08-23T15:45:41Z
html.description.abstract<p>The spread of SARS-CoV-2 and ongoing COVID-19 pandemic underscores the need for new treatments. Here we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1alpha RNase endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against use of non-medical formulations including edibles, inhalants or topicals as a preventative or treatment therapy at the present time.</p>
dc.identifier.submissionpathcovid19/382
dc.contributor.departmentUMass Center for Clinical and Translational Science
dc.source.pageseabi6110


Files in this item

Thumbnail
Name:
sciadv.abi6110.pdf
Size:
3.845Mb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Except where otherwise noted, this item's license is described as Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).